To include your compound in the COVID-19 Resource Center, submit it here.

Praxis: connecting the neurological dots

Start-up’s neurology programs modulate channels in brain to normalize neuronal firing for epilepsies, mood and movement disorders

Praxis’ neurology pipeline emerged from genetic data that found neuronal imbalances to be at the root of several disorders that were previously thought to be unrelated. The company debuted this month with $100 million in funding, three clinical programs and a partnership with Ionis.

Incubated by Clarus Ventures in 2016, Praxis Precision Medicines Inc.’s initial focus was genetic epilepsy. The company has also received funding from Blackstone Life Sciences, Novo Holdings, Vida Ventures and Eventide.

The company was analyzing whole

Read the full 790 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers